Research On Financing Of HR Heilongjiang Pharmaceutical Co.,Ltd. Under The Background Of Two-invoice System

2008 on deepening the opinions of the medical and health system reform draft issued and solicit opinions from the public.The publication of”opinion "pulled open the prelude to a new round of medical and health system reform in our country,to our country the whole health system will be significant and long-term impact.As the middle part of the healthcare system,circulation pharmaceutical enterprises will face unprecedented challenges and opportunities for development.On the other hand,the medicine circulation industry of our country in recent years,the sharp change is toward large-scale,modernization and informatization development.At the same time,countries drug prices,medical education,vigorously develop the rural market,speed up the certification and a series of the pharmaceutical industry policy.The industry environment is very complex,this article is under the background of the domestic drugs under the policy of"Two-invoice System"commercial company financing problems have a certain understanding,and has carried on the preliminary research and analysis,find out of"Two-invoice System"on the influence factors of pharmaceutical commercial enterprises financing.In this paper,literature analysis,investigation and case analysis methods are used to study this paper,mainly includes the following several parts: the first chapter introduction including the research purpose and significance,research status at home and abroad,the main content and research methods of this study;The second chapter expounds the financing of relevant concepts and theoretical basis,including the concept of corporate financing;Corporate finance theory base,mainly introduced through the bank financing,social financing,such as enterprise financing way,and compare the advantages and disadvantages of various ways;The third chapter introduces the current situation of traditional medicine business enterprise financing situation,including the policy of "Two-invoice System" from the process is put forward to fall to the ground,theoretical basis,and has been on a trial basis "Two-invoice System" region and has not been implemented in the "Two-invoice System" contrast.And an overview of the "Two-invoice System" pilot area medicine business enterprise itself in the financiers in the face of policy response and effect;The fourth chapter in details about the enterprise in the "Two-invoice System" under the influence of capital chain affected by specific,analysis of the specific reasons,the most important thing is that the industry should be collect leisurely period was longer,enterprise capital chain tension,and "Two-invoice System" cause drug purchase price increase,and the phase constant,enterprise capital turnover pressure increases,so the more dependent on financing.The reasonable financing for enterprises solve the problem of the stress of cash flow,financing methods and scientific selection can reduce the risk of financing and reduce the cost of financing for the enterprise.Thefifth chapter on the financing of pharmaceutical commercial enterprises are the most common way to statistics,query large data to understand the "Two-invoice System" policy appeared before and after the change of medical enterprise financing way choice data,the cause of changes from the realistic analysis.At the same time analysis the situation of foreign pharmaceutical drug supply business industry,and its financing model,analyzes its advantages and disadvantages,compared with domestic "Two-invoice System",using the experience of its advantages,for domestic pharmaceutical commercial enterprises financing when the choice to provide the reference in the future.Sixth chapter analyze government full policy landing time and conditions in the "Two-invoice System",a short period of time in the future,there may be a large number of small pharmaceutical commercial enterprises in the industry is large and medium-sized pharmaceutical enterprise annexation,and large and medium-sized pharmaceutical commercial enterprises at this stage need to consider acquiring capital pressure,on this basis for large and medium-sized pharmaceutical commercial enterprises in financing for a rainy day.Chapter vii conclusion.